152 related articles for article (PubMed ID: 37939133)
1. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
Arrieta VA; Duerinck J; Burdett KB; Habashy KJ; Geens W; Gould A; Schwarze JK; Dmello C; Kim KS; Saganty R; Chen L; Moscona A; McCord M; Lee-Chang C; Horbinski CM; Zhang H; Stupp R; Neyns B; Sonabend AM
Clin Cancer Res; 2024 Jan; 30(2):379-388. PubMed ID: 37939133
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J; Schwarze JK; Awada G; Tijtgat J; Vaeyens F; Bertels C; Geens W; Klein S; Seynaeve L; Cras L; D'Haene N; Michotte A; Caljon B; Salmon I; Bruneau M; Kockx M; Van Dooren S; Vanbinst AM; Everaert H; Forsyth R; Neyns B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168003
[TBL] [Abstract][Full Text] [Related]
3. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
Arrieta VA; Chen AX; Kane JR; Kang SJ; Kassab C; Dmello C; Zhao J; Burdett KB; Upadhyayula PS; Lee-Chang C; Shilati J; Jaishankar D; Chen L; Gould A; Zhang D; Yuan J; Zhao W; Ling X; Burks JK; Laffleur B; Amidei C; Bruce JN; Lukas RV; Yamaguchi JT; Cieremans D; Rothschild G; Basu U; McCord M; Brat DJ; Zhang H; Cooper LAD; Zhang B; Sims P; Cloughesy TF; Prins R; Canoll P; Stupp R; Heimberger AB; Horbinski C; Iwamoto FM; Rabadan R; Sonabend AM
Nat Cancer; 2021 Dec; 2(12):1372-1386. PubMed ID: 35121903
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract][Full Text] [Related]
7. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
10. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
13. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
15. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
16. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
17. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC; Ugurel S; Leiter U; Meier F; Gutzmer R; Haferkamp S; Zimmer L; Livingstone E; Eigentler TK; Hauschild A; Kiecker F; Hassel JC; Mohr P; Fluck M; Thomas I; Garzarolli M; Grimmelmann I; Drexler K; Spillner AN; Eckhardt S; Schadendorf D;
Lancet; 2023 Sep; 402(10404):798-808. PubMed ID: 37451295
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]